Advertisement

Myasthene Syndrome

  • W. Müllges
  • R. Gold
  • M. Blobner
  • K. V. Toyka

Zusammenfassung

Ein myasthenes Syndrom ist gekennzeichnet durch mehr oder weniger stark fluktuierende, unterschiedlich rasch (über Tage, Wochen) progrediente, schmerzlose abnorme Erschöpfbarkeit und Muskelschwäche, die zumeist generalisiert, seltener fokal bulbär oder okulär betont ist.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Arsura EL, Brunner NG, Namba T, Grob D (1985) High-dose methylprednisolone in myasthenia gravis. Arch Neurol 42:1149–1153.CrossRefPubMedGoogle Scholar
  2. Drachman DB (1994) Myasthenia gravis. N Engl J Med 331:1797–1807.CrossRefGoogle Scholar
  3. Gajdos P et al. (1993) A randomized trial comparing prednisolone and azathioprine in myasthenia gravis. J Neurol Neurosurg Psychiatr 56:1157–1163.CrossRefGoogle Scholar
  4. Gajdos P, Chevret S, Clair B et al. (1997) Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Ann Neurol 41:789–796.CrossRefPubMedGoogle Scholar
  5. Grob D, Simpson D, Mitsumoto H et al. (1995) Treatment of myasthenia gravis by immu-noadsorption of plasma. Neurology 45:338–344.CrossRefPubMedGoogle Scholar
  6. Heininger K, Hendricks M, Toyka KV (1985) Myasthenia gravis. A new semiselective procedure to remove acetylcholine receptor autoantibodies from plasma. Plasma Ther 6:771–775.Google Scholar
  7. Hibbs RG, Weber JT, Corwin A et al. (1996) Experience with the use of an investigational F(ab’)2 heptavalent botulism immune globulin. Clin Infect Dis 23:337–340.CrossRefPubMedGoogle Scholar
  8. Hohlfeld R, Toyka KV (1993) Therapies in myasthenia gravis. In: DeBaets NH, Oosterhuis HJGH (eds) Myasthenia gravis. CRC Press, Boca Raton, pp 235–261.Google Scholar
  9. Lennon VA, Kryzer TJ, Griesmann GE et al. (1995) Calcium channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med 332:1467–1474.CrossRefPubMedGoogle Scholar
  10. Maselli RA, Ellis W, Mandler RN et al. (1997) Cluster of wound botulism in california: clinical, electrophysiologic, and pathologic study. Muscle Nerve 20:1284–1295.CrossRefPubMedGoogle Scholar
  11. McEvoy KM, Windebank AJ, Daube JR, Low PA (1989) 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthénic syndrome. N Engl J Med 321:1567–1571.CrossRefPubMedGoogle Scholar
  12. Oosterhuis HJGH (1997) Myasthenia gravis. Groningen Neurological Press, Groningen.Google Scholar
  13. Palace J, Newsom-Davis J, Lecky B, and the Myasthenia Gravis Study Group (1998) A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Neurology 50:1778–1783.CrossRefPubMedGoogle Scholar
  14. Sanders DB (1995) Lambert-Eaton myasthénie syndrome. Ann Neurol 37:S63–73.CrossRefPubMedGoogle Scholar
  15. Smith AG, Wald J (1996) Acute ventilatory failure in Lambert-Eaton myasthénic syndrome and its response to 3,4-diaminopyridine. Neurology 46:1143–1145.CrossRefPubMedGoogle Scholar
  16. Thomas CE, Mayer SA, Gungor Y et al. (1997) Myasthenie crisis: clinical features, mortality, complications, and risk factors or prolonged intubation. Neurology 48:1253–1260.CrossRefPubMedGoogle Scholar
  17. Thornton CA, Griggs RC (1994) Plasma exchange and intravenous immunoglobulin treatment of neuromuscular disease. Ann Neurol 35:260–268.CrossRefPubMedGoogle Scholar
  18. Toyka KV (1991) Myasthenia gravis. In: Kassirer JP (ed) Current Therapy in Internal Medicine, 3rd edn. Decker, Philadelphia, pp 1704–1710.Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1999

Authors and Affiliations

  • W. Müllges
  • R. Gold
  • M. Blobner
  • K. V. Toyka

There are no affiliations available

Personalised recommendations